Tuesday, Mar 8, 1994

FDA Grants Genentech License to Market Nutropin for Growth Hormone Deficiency in Children

Only human growth hormone (hGH) product with two indications

South San Francisco, Calif. -- March 8, 1994 --

Genentech, Inc. announced today that it received permission from the Food and Drug Administration (FDA) to market Nutropin (somatropin [rDNA origin] for injection) hGH for the treatment of children with growth failure due to inadequate levels of the natural hormone in their bodies.

This marketing approval is the second to be granted by the FDA for Nutropin, occurring less than four months after Genentech received approval to market Nutropin for treating growth failure in children due to chronic renal insufficiency prior to kidney transplantation. Nutropin is the only hGH product approved for more than one indication.

"Nutropin's development and these approvals demonstrate both Genentech's and the FDA's commitment to treating serious growth disorders," said G. Kirk Raab, Genentech's president and chief executive officer.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. The company has headquarters in South San Francisco, Calif., and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.

# # #